Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/22/2026

1. SPY
2. WBD
3. PSKY
4. NVDA
5. TSLA
6. USO
7. AMD
8. COHR
9. META
10. AMC

Go back to Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan
(NASDAQ: RYTM) Delayed: 98.83 +1.12 (1.15%)
Previous Close $97.71    52 Week High $ 
Open $98.47    52 Week Low $ 
Day High $100.76    P/E N/A 
Day Low $97.54    EPS $ 
Volume 613,603